← Back to Clinical Trials
Recruiting NCT07629791

NCT07629791 Effects of Augmented Reality (AR) and Transcranial Direct Current Stimulation (tDCS)

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07629791
Status Recruiting
Phase
Sponsor Riphah International University
Condition Stroke
Study Type INTERVENTIONAL
Enrollment 28 participants
Start Date 2026-05-20
Primary Completion 2026-10-20

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 90 Years
Study Type INTERVENTIONAL
Interventions
Augmented reality combined with tDCS & Convention therapyAugmented reality combined with Sham & Convention therapy

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 28 participants in total. It began in 2026-05-20 with a primary completion date of 2026-10-20.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The aim of this randomized controlled trial is to determine the effects of Augmented Reality (AR)-based balance training on improving balance and postural control in chronic stroke survivors and whether the addition of transcranial Direct Current Stimulation (tDCS) to AR training produces superior outcomes compared to AR training alone.

Eligibility Criteria

Inclusion Criteria: * Balance impairment confirmed by Berg Balance Scale (BBS) score 21-44. * Age between 18-90 years. * Mild or no spasticity in lower limb (MAS ≤ 2) * have sufficient cognition to follow the instructions provided by the therapists and the computer. Exclusion Criteria: * Individuals with implanted electronic devices (e.g., pacemakers), due to interaction risk with tDCS * Other medical or psychological conditions affecting participation (e.g., severe pain, epilepsy, pacemaker). * Patients with severe cognitive deficits or visual impairments

Contact & Investigator

Central Contact

Abrish H Abbasi

✉ abrish.habib@riphah.edu.pk

📞 03155311799

Principal Investigator

Aaleen Fatima, MS-NMPT*

PRINCIPAL INVESTIGATOR

Riphah International Unversity

Frequently Asked Questions

Who can join the NCT07629791 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 90 Years, studying Stroke. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07629791 currently recruiting?

Yes, NCT07629791 is actively recruiting participants. Contact the research team at abrish.habib@riphah.edu.pk for enrollment information.

Where is the NCT07629791 trial being conducted?

This trial is being conducted at Rawalpindi, Pakistan.

Who is sponsoring the NCT07629791 clinical trial?

NCT07629791 is sponsored by Riphah International University. The principal investigator is Aaleen Fatima, MS-NMPT* at Riphah International Unversity. The trial plans to enroll 28 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology